Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram
- 31 January 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 177 (1), 107-112
- https://doi.org/10.1016/j.juro.2006.08.068
Abstract
Purpose: Screening with serum prostate specific antigen testing leads to the detection of many prostate cancers early in their natural history. Statistical models have been proposed to predict indolent cancer. We validated and updated model predictions for a screening setting. Materials and Methods: We selected 247 patients with clinical stage T1C or T2A from the European Randomized Study on Screening for Prostate Cancer who were treated with radical prostatectomy. We validated a nomogram that had previously been developed in a clinical setting. Predictive characteristics were serum prostate specific antigen, ultrasound prostate volume, clinical stage, prostate biopsy Gleason grade, and total length of cancer and noncancer tissue in biopsy cores. Indolent cancer was defined as pathologically organ confined cancer 0.5 cc or less in volume without poorly differentiated elements. Logistic regression was used to update the previous model and examine the contribution of other potential predictors. Results: Overall 121 of 247 patients (49%) had indolent cancer, while the average predicted probability was around 20% (p <0.001). Effects of individual variables were similar to those found before and discriminative ability was adequate (AUC 0.76). An updated model was constructed, which merely recalibrated the nomogram and did not apply additional predictors. Conclusions: Prostate cancers identified in a screening setting have a substantially higher likelihood of being indolent than those predicted by a previously proposed nomogram. However, an updated model can support patients and clinicians when the various treatment options for prostate cancer are considered.Keywords
This publication has 19 references indexed in Scilit:
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Natural History of Early, Localized Prostate CancerJama-Journal Of The American Medical Association, 2004
- Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)BJU International, 2003
- Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined TumorsJournal of Urology, 2003
- Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trialInternational Journal of Cancer, 2001
- HISTOPATHOLOGICAL PROSTATE CANCER CHARACTERISTICS AT RADICAL PROSTATECTOMY AFTER POPULATION BASED SCREENINGJournal of Urology, 2000
- Prospective Evaluation of Men With Stage T1C Adenocarcinoma of the ProstateJournal of Urology, 1997
- The biologic dilemma of early carcinoma of the prostateCancer, 1996
- Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancerJAMA, 1994
- Prostate cancer: to screen or not to screen?BMJ, 1993